# Junta clínica — PT-pseudo_c03b1168ff4d (tarea 1)

## Intervención 1 — INTAKE

*the record clerk; reads the file out loud and interprets nothing* · vuelta 1

Colleagues, this is the record as it arrived, field by field. I read it out and interpret nothing; everything after this is yours.

{
  "case_id": "PT-pseudo_c03b1168ff4d",
  "pid": "PT-pseudo_c03b1168ff4d",
  "task": 1,
  "psa": 7.8,
  "age": 74,
  "months": 2,
  "pirads": "4",
  "psad": 0.165,
  "psav": 1.2,
  "psap": 6.3,
  "vol": 47.17,
  "dre": "Normal",
  "bx": "Positive",
  "cspca": 0.75055045,
  "medhx": "Hypertension, Hypercholesterolaemia, Chronic kidney disease",
  "meds": "valsartan, lisinopril, atorvastatin, simvastatin, rosuvastatin",
  "notes": "PSA 7.8 ng/mL. PI-RADS 4. PSAD 0.17. Prostate volume 47 mL. csPCa 0.75.",
  "pmhx": [
    "Hypertension",
    "Hypercholesterolaemia",
    "Chronic kidney disease"
  ],
  "allergies": [],
  "vitals": {
    "weight": "87 kg",
    "height": "184 cm",
    "bmi": "25.7",
    "bp": "143/82 mmHg",
    "hr": "81 bpm",
    "smoking": "Ex-smoker (34 pack-yr, quit 2006)",
    "last_dental": "1 yr ago",
    "flu_vax": "Oct 2024"
  },
  "enc_dept": "Urology - outpatient",
  "enc_date": "05 Jan 2025",
  "enc_ref": "Dr. E. Mulder (GP)",
  "enc_type": "Re-evaluation - prior PCa diagnosis",
  "note_sections": [
    {
      "s": "Chief complaint",
      "t": "Rising PSA levels combined with a previous positive biopsy mandate a current clinical reassessment."
    },
    {
      "s": "History",
      "t": "A confirmed prostate malignancy now requires surveillance, following initial PSA investigation in mid-2022. The subject is a 74-year-old ICT consultant who remains married and resides alone, though his adult son lives in close proximity. Tobacco use ceased in 2006, following a 34 pack-year accumulation. Physical activity remains high, comprising three weekly five-kilometre runs, with no alcohol consumption. Distance to the clinic exceeds 90 minutes, and telephone consultations are preferred. Lower urinary tract symptoms are pronounced, yielding an IPSS score of 26. Hypertension, hypercholesterolaemia, and chronic kidney disease form the background of his medical history. Current pharmacotherapy consists of valsartan, lisinopril, atorvastatin, simvastatin, and rosuvastatin. Recent preventive care included a routine colonoscopy and audiology evaluation, while his latest cardiology review returned unremarkable."
    },
    {
      "s": "Physical examination",
      "t": "Digital rectal examination yields normal findings: a symmetrically enlarged gland with a smooth, firm consistency and no palpable nodules or asymmetry. Vital sign measurements record 143/82 mmHg for blood pressure and 81 bpm for heart rate. A general physical assessment notes a BMI of 25.7, alongside clear pulmonary fields, a regular cardiac rhythm, and an absence of peripheral oedema."
    }
  ],
  "occupation": "ICT consultant",
  "marital": "Married",
  "living": "Lives alone; adult son nearby",
  "next_of_kin": "Adult son (primary contact)",
  "recent_other": [
    "Gastroenterology — surveillance colonoscopy",
    "Audiology — hearing test"
  ],
  "alcohol": "0 units / week (alcohol-free)",
  "exercise": "Running 3x/week, 5 km",
  "ipss": "IPSS score: 26/35 (severe LUTS)",
  "admin": "Lives >90 min from clinic; phone follow-up preferred where clinically safe.",
  "mri_hospital": "Spaarne Gasthuis (Haarlem)",
  "ct": null,
  "active_treatment_flag": 0
}

## Intervención 2 — INTAKE

*the record clerk; reads the file out loud and interprets nothing* · vuelta 1

And this is the same record as the reading form presents it — the panel the urologist sees up front, with the masked documents named but not shown.

You are a senior urologist reviewing a patient case. The structured clinical
record below is shown to you up front, exactly as in the reading form. Some
documents are not shown and must be pulled up via the available tools
(radiology / MRI report, pathology report, previous notes, laboratory
results, PSA history, and the family-history anamnesis) when you need to
consult them.

Case ID: PT-pseudo_c03b1168ff4d
Task: 1

Encounter: Urology - outpatient on 05 Jan 2025.
Referrer: Dr. E. Mulder (GP).
Type: Re-evaluation - prior PCa diagnosis.

Clinical data (read-only — values loaded from the record):
  - 74-year-old male
  - PSA: 7.8 ng/mL
  - mpMRI — PI-RADS score: 4 (1–2 low · 3 equivocal · 4–5 high risk)
  - PSA density: 0.165 ng/mL²
  - PSA velocity: 1.2 ng/mL/yr
  - Prior PSA: 6.3 ng/mL
  - Prostate volume: 47.17 mL
  - Months since last PSA: 2
  - DRE findings: Normal (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done)
  - Prior biopsy: Positive (None · Negative · ASAP/HGPIN · Positive)
  - csPCa predicted probability: 0.75055045 (clinically significant PCa = ISUP ≥ 2)

Medical history & medication:
  - Medical history: Hypertension, Hypercholesterolaemia, Chronic kidney disease
  - Problem list / PMHx: Hypertension, Hypercholesterolaemia, Chronic kidney disease
  - Current medication: valsartan, lisinopril, atorvastatin, simvastatin, rosuvastatin
  - Allergies: NKA
  - Additional notes: PSA 7.8 ng/mL. PI-RADS 4. PSAD 0.17. Prostate volume 47 mL. csPCa 0.75.

Vitals: weight 87 kg, height 184 cm, BMI 25.7, BP 143/82 mmHg, HR 81 bpm. Smoking: Ex-smoker (34 pack-yr, quit 2006).

Chief complaint: Rising PSA levels combined with a previous positive biopsy mandate a current clinical reassessment.

History: A confirmed prostate malignancy now requires surveillance, following initial PSA investigation in mid-2022. The subject is a 74-year-old ICT consultant who remains married and resides alone, though his adult son lives in close proximity. Tobacco use ceased in 2006, following a 34 pack-year accumulation. Physical activity remains high, comprising three weekly five-kilometre runs, with no alcohol consumption. Distance to the clinic exceeds 90 minutes, and telephone consultations are preferred. Lower urinary tract symptoms are pronounced, yielding an IPSS score of 26. Hypertension, hypercholesterolaemia, and chronic kidney disease form the background of his medical history. Current pharmacotherapy consists of valsartan, lisinopril, atorvastatin, simvastatin, and rosuvastatin. Recent preventive care included a routine colonoscopy and audiology evaluation, while his latest cardiology review returned unremarkable.

Physical examination: Digital rectal examination yields normal findings: a symmetrically enlarged gland with a smooth, firm consistency and no palpable nodules or asymmetry. Vital sign measurements record 143/82 mmHg for blood pressure and 81 bpm for heart rate. A general physical assessment notes a BMI of 25.7, alongside clear pulmonary fields, a regular cardiac rhythm, and an absence of peripheral oedema.

Patient info: ICT consultant; Married; Lives alone; adult son nearby.
Next of kin: Adult son (primary contact).

Lifestyle: alcohol 0 units / week (alcohol-free); exercise Running 3x/week, 5 km; IPSS score: 26/35 (severe LUTS).

Recent other appointments: Gastroenterology — surveillance colonoscopy; Audiology — hearing test.
Admin: Lives >90 min from clinic; phone follow-up preferred where clinically safe.

Information you can request via tools (the masked "Extended EHR view" — what
the urologist would actively pull up during the consult):
  - radiology / MRI report (full mpMRI prose behind the headline imaging values)
  - pathology report (any prior biopsy on record)
  - previous GP / urology consultation notes
  - laboratory results (full panel)
  - PSA history (trend / velocity beyond the headline value)
  - family history of prostate cancer (anamnesis)

Question:
Based on this patient's data, do you recommend biopsy?


One correction to that last paragraph before anybody acts on it: the documents this task actually serves are radiology_report, psa_trend, previous_notes, laboratory_results, plus the family-history anamnesis. There is NO pathology report to pull up in a task-1 biopsy decision — the prior-biopsy status on the panel above is all the pathology on record, and whatever the previous notes say about it. Nobody should ask for one, and nobody should quote one.

## Intervención 3 — EXPERT-STRUCTURED

*Expert 1, Extra-Trees on the structured panel only; opening bid with an error bar* · vuelta 1

Expert 1 here — the classifier that reads the structured panel and nothing else. My bid:

SUGGESTION: BIOPSY   p(biopsy) = 0.67
  uncertainty  +/- 0.15 epistemic (95% band 0.39-0.96); among patients I cannot tell apart the outcome was 0.91 of 1.00 mixed
  reliability  MODERATE ('supports' tier) — out-of-fold it was right 60% of the time over the 20 labelled cases in this tier

What moved me most, across the labelled series: prior positive biopsy, PI-RADS >= 4, no prior biopsy, pmhx_hypercholesterolaemia, suspicious DRE, number of comorbidities. I read 39 variables, all
from the panel — nothing from the mpMRI prose, the PSA trajectory, the previous notes or the
laboratory. Out-of-fold over 91 labelled cases: AUC 0.758, balanced
accuracy 0.625.

The final call is the chair's.

## Intervención 4 — EXPERT-COHORT

*cohort criterion; what the labelled series did in this exact situation* · vuelta 1

This patient's situation: prior positive biopsy. The panel alone does not answer, and that is the finding.

The criterion here is that the visible panel does not determine this decision: he already has a tissue diagnosis, so neither a high PI-RADS nor a rising PSA is new information. What decides it is the documented grade of the prior biopsy and the surveillance history, which live in the previous notes. Measured on the labelled series: none of the three panel
rules I carry for this situation (PSA >= 20, age >= 78, PI-RADS <= 2) applies to him, and among the
39 remaining labelled men in this situation no structured variable separates the two answers.

REGISTRAR: the previous notes are where this case is decided. Read them for the grade of the prior
biopsy (Gleason or ISUP), the number of biopsy sessions and their dates, and whether he is on a
surveillance protocol with a confirmatory biopsy due. Do not read this as 'defer' and do not read it
as 'biopsy'.

## Intervención 5 — EXPERT-LIBRARY

*case library; the closest labelled precedents and what the reading urologist did with them* · vuelta 1

The case library holds 48 labelled men in this same situation (Positive prior biopsy). The 3 closest by panel distance, and what the reading urologist did:
  1. distance 1.02: PI-RADS 4, PSA 4.5, PSAD 0.08, age 73, DRE Normal -> BIOPSY (borderline). He wrote: "Favourable risk intermediate risk PC in 73 yr old. Unclear when previous MRI+bx was performed. Reasonable to recommend another biopsy approx 2yrs after the first, especi…"
  2. distance 1.08: PI-RADS 4, PSA 6.7, PSAD 0.2, age 67, DRE Normal -> BIOPSY (borderline). He wrote: "Active surveillance, only one previous biopsy 2 yrs ago. Stable findings (stable PIRADS4, slightly increasing PSA) -> borderline indication for biopsy. As only one previ…"
  3. distance 1.12: PI-RADS 4, PSA 4.1, PSAD 0.181, age 72, DRE Normal -> BIOPSY (borderline). He wrote: "Borderline older patient, favorable intermediate risk disease with perineurial features. Low PSA (why was he biopsied in 2023 under non-elevated PSA?). While only one pr…"

PRECEDENT: BIOPSY (weighted vote 1.00 for biopsy). Distance-weighted precedent is no better than chance here (0.47 leave-one-out): read the precedents for how this urologist reasons, not for the answer.

What the precedents are FOR: they show what this urologist looks at and how he phrases the call. What they are NOT: facts about this patient. Nobody may cite a precedent's grade, PSA or MRI as if it were his.

## Intervención 6 — EXPERT-TRACE

*Expert 4, trace model; which documents the reading urologist opens and what he weighs in this situation* · vuelta 1

Expert 4 here — the model of how the reading urologist works a case like this. Predicted from his 48 labelled traces in this situation (Positive prior biopsy): a per-field model where it beats the mode out of fold (prior-biopsy weight, DRE weight, PI-RADS weight, and whether he opens the laboratory), the mode elsewhere.

WHAT HE OPENS: radiology_report, psa_trend, previous_notes, laboratory_results.
WHAT HE WEIGHS: bx=important, fh=noted, age=important, dre=noted, psa=important, vol=noted, psad=noted, pirads=important, comorbidity=noted.
HOW SURE HE USUALLY IS: clear.

MODERATOR: that list of documents is the plan — exactly those, no more. Every document opened beyond what
he would open is scored against the conference as an unnecessary reveal; every document left closed
leaves a variable he weighed without its source. Attach the question each one must answer.

## Intervención 7 — EXPERT-EAU

*EAU guideline specialist; speaks only from the guideline text he retrieved* · vuelta 1

GUIDELINE
The guideline addresses the use of MRI and biopsy in the context of prostate cancer risk stratification. It states that a stable MRI (PRECISE 1-3) does not make a repeat biopsy superfluous but it might be excluded in patients with low-risk tumour and a stable low PSA-D < 0.15.

WHAT THE EXPERTS' BIDS DO NOT SETTLE
EXPERT-STRUCTURED, I disagree with the suggestion of biopsy because the guideline emphasizes that a stable MRI and low PSA-D can exclude the need for repeat biopsy.
EXPERT-COHORT, the cohort criterion confirms that the decision is not determined by the panel variables alone, as the documented grade of the prior biopsy and surveillance history is the deciding factor.

WHAT THE DOCUMENTS MUST SETTLE
previous_notes - the documented grade of the prior biopsy: at ISUP 2 or above the guideline sends him to treatment, not to more tissue; if it is unrecorded the indication stands
radiology_report - whether the lesion is compared against an earlier study: unchanged does not support re-sampling, new or larger does
psa_trend - the PSA velocity: the guideline does not provide a specific threshold for PSA velocity in this context, but the context suggests a rising trend is relevant.
laboratory_results - the PSA density: the guideline suggests a PSA-D < 0.15ng/mL/cc may be relevant in excluding repeat biopsy.

## Intervención 8 — MODERATOR

*chairs the discussion; sets the open questions and assigns the documents* · vuelta 1

This case hinges entirely on the documented grade of the prior biopsy and the surveillance plan detailed in the previous notes.

The documents for this session were fixed by EXPERT-TRACE; what I add is the question each one has to answer, and the open questions for the room.

REGISTRAR — pull these up, and answer exactly the question attached to each:
  radiology_report (get_mri_report) -> Does the lesion size or zone in the MRI report indicate a new or larger lesion compared to an earlier study?
  psa_trend (get_psa_trend) -> What is the PSA velocity, and is a rising trend relevant to the decision?
  previous_notes (get_previous_notes) -> What is the documented grade of the prior biopsy (Gleason/ISUP), the number and dates of biopsy sessions, and whether he is on a surveillance protocol with a confirmatory biopsy due?
  laboratory_results (get_lab_results) -> Does the PSA density meet the guideline threshold of < 0.15 ng/mL/cc for excluding repeat biopsy?

OPEN QUESTIONS for this conference — these are what the decision hangs on:
  Q1. What is the documented grade (Gleason/ISUP) of the prior biopsy?
  Q2. Is the documented grade of the prior biopsy ISUP 2 or above, which would mandate treatment according to the guideline?

On the plan itself: Dropped 1 question(s) that asked for a value already printed on the panel: "Does the PSA density (0.165 ng/mL²) meet the guideline threshold of < 0.15 ng/mL/cc for excluding repeat biopsy?".

## Intervención 9 — REGISTRAR

*the registrar who pulls up documents; reports what they say, nothing else* · vuelta 1

WHAT I FOUND
radiology_report
COMPARISON: new
LESION: size and zone of the index lesion, as the report words it: "asymmetric hypointense area within the left peripheral zone spanning the base to mid section, sized roughly 14 x 11 x 16 mm."

psa_trend
What is the PSA velocity, and is a rising trend relevant to the decision?: The PSA velocity is 1.2 ng/mL/yr, and the trend is rising.

previous_notes
What is the documented grade of the prior biopsy (Gleason/ISUP), the number and dates of biopsy sessions, and whether he is on a surveillance protocol with a confirmatory biopsy due?: The documented grade of the prior biopsy is not explicitly stated in the retrieved notes, but there was one biopsy session on "16 January 2023" which returned positive for malignancy. He is on ongoing monitoring.

laboratory_results
Does the PSA density meet the guideline threshold of < 0.15 ng/mL/cc for excluding repeat biopsy?: The PSA density is 0.165 ng/mL/mL, which does not meet the guideline threshold of < 0.15 ng/mL/cc.

WHAT I DID NOT OPEN
family-history anamnesis, because the decision hinges on the documented prior biopsy status and surveillance plan.

WHAT THIS SUPPORTS
FOR sampling this patient now
Prior positive biopsy noted in previous notes.
PI-RADS 4 finding on MRI suggests a clinically significant lesion.

AGAINST sampling this patient now
The documented grade of the prior biopsy is not explicitly stated in the retrieved notes.
The PSA density of 0.165 ng/mL/mL does not meet the guideline threshold for exclusion.

WHERE THIS LEANS
LEAN: biopsy

## Intervención 10 — EXPERT-PSA

*Expert 2, PSA projector; the trajectory behind the headline PSA, with a conformal band* · vuelta 1

Expert 2 here — the PSA projector. I read only the serial PSA the registrar opened.

TRAJECTORY: RISING (borderline). Last value 7.80 ng/mL over 3 points spanning 31 months; velocity +2.45 ng/mL per year; doubling time about 13 months.
PROJECTION at 6 months: 11.8 ng/mL, conformal 95% band 3.4-41.2.

Read the band before the point: it is wide by construction, and I only call a direction when the whole
band clears the last value. This does not vote on the biopsy — a rising PSA in a man with a known
diagnosis is the disease behaving as known — it tells the chair how fast the number is moving.

## Intervención 11 — EXPERT-FUSION

*Expert 3, Extra-Trees on panel + laboratory + MRI prose; speaks only on documents that were opened* · vuelta 1

Expert 3 here — the fusion classifier. I read the panel, the mpMRI report and the laboratory panel; nothing from the previous notes or the PSA series.

SUGGESTION: BIOPSY   p(biopsy) = 0.65
  uncertainty  +/- 0.16 epistemic (95% band 0.33-0.97), of which 0.00 comes from values that had to be imputed
  reliability  LOW ('discuss' tier) — out-of-fold it was right 61% of the time over the 31 labelled cases in this tier

What moved me most across the labelled series: prior positive biopsy, no prior biopsy, free PSA < 15%, DWI restriction in the report, lesion >= 15 mm in the report, suspicious DRE. Out-of-fold AUC 0.794. I am the only expert that has read the report's wording, and I still cannot see the prior grade or the
surveillance history: those are in the notes, and the registrar has to carry them.

## Intervención 12 — PANEL-PROTOCOL

*the panel's written protocol; consolidates the experts by rule and says which rule fired* · vuelta 1

The panel protocol, applied to what is on the board:

  EXPERT-STRUCTURED  BIOPSY, p(biopsy)=0.67  ('supports' tier; weight 2.0)
  EXPERT-FUSION      BIOPSY, p(biopsy)=0.65  ('discuss' tier, fusion_full; weight 1.5)
  EXPERT-LIBRARY     BIOPSY, p(biopsy)=1.00  (k=3 precedents; does not vote)

  documented prior grade in the opened documents: none recorded

RULE THAT FIRED: weighted vote of the trained experts, p = 0.66 — carried by weighted panel.
PANEL ANSWER: BIOPSY. EXPERT-STRUCTURED carried the most weight ('supports' tier). In this bucket no rule applied and the documents did not record the prior grade, so the trained experts decide.

Confidence the trace model expects here: clear. Weights it expects: bx=important, fh=noted, age=important, dre=noted, psa=important, vol=noted, psad=noted, pirads=important, comorbidity=noted.

CHAIR: this is the panel's position. You sign it, and you write why in the room's words — naming what the registrar retrieved. If you believe a retrieved finding overturns it, name that finding with its value; the burden is on the finding, not on the panel.

## Intervención 13 — VERIFIER

*second EAU reader; checks against the guideline whether this can be decided yet* · vuelta 1

SUFFICIENCY
The documents retrieved by the registrar appear to have addressed the moderator's questions to the extent possible. The `previous_notes` indicated a biopsy on January 16, 2023, but the documented grade (Gleason/ISUP) was not explicitly stated. The `laboratory_results` showed a PSA density of $0.165 \text{ ng/mL/mL}$, which did not meet the guideline threshold of $< 0.15 \text{ ng/mL/cc}$.

ALIGNMENT WITH THE PANEL
The panel protocol concluded with a BIOPSY based on a weighted vote, noting that the documented prior grade was not recorded in the opened documents. The retrieved findings—specifically the lack of a documented grade and the PSA density not meeting the exclusion threshold—do not directly overturn the panel's decision, as the panel relied on the trained experts when the required data was absent.

THE OPEN QUESTIONS, ONE BY ONE
Q1. What is the documented grade (Gleason/ISUP) of the prior biopsy? This remains unanswered, as the `previous_notes` stated the grade was not explicitly documented.
Q2. Is the documented grade of the prior biopsy ISUP 2 or above, which would mandate treatment according to the guideline? This cannot be answered without the grade from the notes.

WHAT CARRIES WEIGHT, AND WHY
The documented grade of the prior biopsy is the most critical variable because the EAU guideline explicitly states that a grade of ISUP 2 or above mandates treatment, and the `previous_notes` are the source for this information. The PSA density not meeting the threshold is also relevant as it suggests exclusion criteria are not met.

MY SUGGESTION TO THE CHAIR
Given that the critical information regarding the prior biopsy grade is missing from the retrieved notes, the decision cannot be definitively made according to the guideline's mandate. Therefore, the case is not ready for a final decision based on the retrieved evidence alone.

VERDICT: not-ready | SUGGEST: defer | MISSING: previous_notes

[The conference closes after pass 1: every document on the plan is open; nothing outside the plan is ever opened. The chair decides on the record as it stands.]

## Intervención 14 — CHAIR

*the senior urologist who signs the decision* · vuelta 1

MY DECISION: BIOPSY   (confidence: clear)

74y male, PSA 7.8, PSAD 0.165, PI-RADS 4, on surveillance after one prior positive biopsy. Prior ISUP grade not recorded, and PSA is rising at 1.2 ng/mL/yr. The lack of prior grade necessitates sampling to determine management pathway. Biopsy recommended for further characterization.

What carried weight: bx=important, age=important, dre=noted, psa=important, vol=noted, psad=noted, pirads=important, comorbidity=noted
Sections retrieved: radiology_report, psa_trend, previous_notes, laboratory_results
